Brighton Jones LLC bought a new position in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,402 shares of the company's stock, valued at approximately $1,021,000.
Several other institutional investors have also recently added to or reduced their stakes in HCA. Benjamin F. Edwards & Company Inc. bought a new position in HCA Healthcare during the second quarter worth $33,000. Legacy Investment Solutions LLC acquired a new stake in shares of HCA Healthcare in the 3rd quarter valued at about $39,000. Canoe Financial LP acquired a new position in HCA Healthcare during the 3rd quarter worth approximately $41,000. Capital Performance Advisors LLP acquired a new stake in HCA Healthcare in the third quarter valued at approximately $41,000. Finally, Northwest Investment Counselors LLC acquired a new position in shares of HCA Healthcare during the third quarter worth approximately $44,000. 62.73% of the stock is owned by institutional investors and hedge funds.
HCA Healthcare Stock Performance
HCA traded down $12.86 during trading hours on Friday, hitting $312.51. The stock had a trading volume of 3,031,283 shares, compared to its average volume of 1,157,521. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71. The stock has a market cap of $79.16 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.09 and a beta of 1.64. HCA Healthcare, Inc. has a 1 year low of $279.93 and a 1 year high of $417.14. The company's fifty day simple moving average is $313.49 and its 200 day simple moving average is $352.87.
HCA Healthcare (NYSE:HCA - Get Free Report) last released its quarterly earnings data on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, beating analysts' consensus estimates of $6.03 by $0.19. HCA Healthcare had a net margin of 8.52% and a return on equity of 520.98%. During the same period last year, the business posted $5.90 earnings per share. Equities analysts anticipate that HCA Healthcare, Inc. will post 21.75 earnings per share for the current year.
Insider Buying and Selling at HCA Healthcare
In related news, insider Erol R. Akdamar sold 2,900 shares of the business's stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the completion of the transaction, the insider now directly owns 6,843 shares in the company, valued at $2,415,579. The trade was a 29.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Phillip G. Billington sold 3,897 shares of the business's stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the transaction, the senior vice president now directly owns 52,702 shares of the company's stock, valued at $18,445,700. The trade was a 6.89 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.
Analyst Ratings Changes
Several research analysts have weighed in on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $392.00 price objective on shares of HCA Healthcare in a report on Tuesday, October 1st. Barclays cut their price target on HCA Healthcare from $396.00 to $392.00 and set an "overweight" rating for the company in a research note on Friday, November 8th. Truist Financial cut their target price on HCA Healthcare from $430.00 to $390.00 and set a "buy" rating on the stock in a research report on Monday, January 6th. JPMorgan Chase & Co. restated a "neutral" rating and set a $380.00 price objective on shares of HCA Healthcare in a research note on Tuesday, December 17th. Finally, StockNews.com lowered shares of HCA Healthcare from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $385.27.
View Our Latest Analysis on HCA Healthcare
About HCA Healthcare
(
Free Report)
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Featured Articles
Before you consider HCA Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list.
While HCA Healthcare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
